our mission: to discover and develop innovative anti-viral and immunological treatments.

Marinomed is a company discovering and developing innovative anti-viral and immunological treatments. The Company's innovative anti-viral respiratory technology platform, mavirex, for the development of broadly active anti-viral treatments has already been proven in clinical trials and on the market by its first marketed product: an anti-viral nasal spray against Common Cold. Marinomed furthermore has a pipeline of proprietary compounds in allergy and autoimmune diseases, which are in development.

RECENT NEWS

11-08-2010	Marinomed’s Antiviral Effective in Clinical Trial for Common Cold - Study published in Respiratory Research
28-06-2010	Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray Against Common Cold
25-05-2010	Marinomed’s MAM-06.301 Achieves Preclinical POC - Study published in BMC Immunology
11-03-2010	Marinomed Granted European Patent For Anti-Viral Active Ingredient
05-10-2009	Carragelose® Shows Promising Antiviral Activity Against Common Cold in Children

MEET MARINOMED AT THE FOLLOWING CONFERENCES:

BIO-Europe 2010: November 15 - 17, 2010, Munich, Germany